July 16, 2026
348
8
2.30%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
4:20Now PlayingMatt Henriksson, Bloomberg Intelligence Senior Equity Analyst, joined Bloomberg's Paul Sweeney and Scarlet Fu to breakdown Abbot Laboratories stronger-than-expected second quarter driven by improved performance across most of its business lines.
Abbott Laboratories raised its 2026 profit guidance after a stronger-than-expected second quarter driven by improved performance across most of its business lines.
The company now expects adjusted earnings to fall between $5.45 to $5.60 a share this year, a 5-cent improvement at the midpoint, it said in a statement Thursday. Profit and sales in the second quarter both surpassed Wall Street estimates.
Shares rose 2.7% in early trading in New York.
Abbott’s device and diabetes businesses modestly beat Wall Street estimates. Its FreeStyle Libre 3 glucose sensors were linked late last year to more than 700 injuries and seven deaths after they were found to be providing incorrect readings.
--------
Watch Bloomberg Radio LIVE on YouTube
Weekdays 7am-6pm ET
Saturday & Sunday 7am-10am ET
Follow us on X
Subscribe to our Podcasts:
Bloomberg Daybreak
Bloomberg Surveillance
Bloomberg Intelligence
Balance of Power
Bloomberg Businessweek
Listen on Apple CarPlay and Android Auto with the Bloomberg Business app:
Apple CarPlay
Android Auto
Visit our YouTube channels:
Bloomberg Podcasts
Bloomberg Television
Bloomberg Originals
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.